"Premium Justified by Structural CDMO Growth"
Order Growth Expected with U.S. Manufacturing Base

According to securities industry analysis, Samsung BioLogics is expected to strengthen its mid- to long-term earnings stability based on the growth of the global contract development and manufacturing organization (CDMO) market and the establishment of a manufacturing base in the United States.


On May 28, KB Securities reported that analyst Shin Jihoon initiated coverage of Samsung BioLogics, stating, "The company’s overwhelmingly high margins and earnings stability compared to peers, as well as expanded order intake following the spin-off of Samsung Bioepis, will drive growth." He issued a "Buy" rating and set a target price of 1.9 million won. This represents 37.3% upside from the previous day's closing price of 1,384,000 won.


Employees are moving at the Samsung BioLogics factory in Yeonsu-gu, Incheon. Photo by Yonhap News Agency

Employees are moving at the Samsung BioLogics factory in Yeonsu-gu, Incheon. Photo by Yonhap News Agency

View original image

The analyst positively assessed the structural growth potential of the CDMO market, citing the increase in biopharmaceutical pipelines (development candidates) and the rising proportion of outsourcing. The high share of products at the commercialization stage, which structurally supports profitability and revenue stability, was highlighted as a key justification for the company’s valuation premium.


Rising utilization rates in production facilities and the establishment of a U.S. manufacturing base are also major growth drivers. The fourth plant ramped up to full operation rapidly last year, while the fifth plant, currently stabilizing operations, is expected to meaningfully contribute to revenue beginning next year. In March, the company acquired GlaxoSmithKline (GSK)’s Rockville, U.S. plant for 353 million dollars, increasing total production capacity to 845,000 liters.


Analyst Shin emphasized, "This will help mitigate tariff risks and enhance access to North American clients, contributing to further order growth in the future." He also noted, "Once revenue recognition from the Rockville plant is fully underway, there is a strong likelihood that the company’s guidance will be revised upward."


Labor union strikes are a short-term risk. Analyst Shin explained, "Wage increases and related costs have already been factored into earnings estimates," adding, "If negotiations are concluded, the resolution of uncertainty could actually serve as a catalyst for a share price increase."



He further stated, "The groundbreaking for the sixth plant, which was delayed last year, is also expected to become a significant growth driver in connection with order performance," and added, "If regulatory sanctions against competitors materialize at the end of the year due to designation under the U.S. Biosecure Act, expectations of indirect benefits for Samsung BioLogics will remain valid."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing